Recombinant Human aAgAB Protein，His

aAgAB recombinant protein is derived from the antigenic components of certain pathogens, particularly focusing on the Ag85 complex found in Mycobacterium tuberculosis and related species. The study of aAgAB is significant for its potential role in diagnostic assays, vaccine development, and understanding immune responses. Mycobacterium tuberculosis remains a major global health challenge, infecting millions and causing tuberculosis. The ability of Ag85 proteins to elicit strong immune responses makes aAgAB a target of interest in immunology and infectious disease research. Previous studies have identified that recombinant forms of these proteins can induce cellular and humoral immunity, leading to protective responses in animal models. This has sparked interest in creating optimized versions of aAgAB for enhanced immunogenicity and stability. Furthermore, research is focused on understanding the structural and functional properties of aAgAB, which could unveil insights into its mechanisms of action and interaction with the host immune system. The versatility of recombinant protein technologies enables modifications that can improve efficacy and safety, paving the way for novel therapeutic strategies against tuberculosis and potentially other diseases caused by pathogenic mycobacteria. Overall, the investigation of aAgAB aligns with broader efforts to combat infectious diseases through innovative vaccine approaches and biomarkers for disease diagnosis, making it a pivotal subject in contemporary biomedical research.